• Intuitive Surgical, ticker NasdaqGS:ISRG, is reporting strong momentum in robotic-assisted surgery.
• The company is highlighting growth in revenue and profitability tied to wider use of its da Vinci and Ion systems.
• Management is also emphasizing new AI integration aimed at improving procedural outcomes and system performance.

For investors, the starting point is the current share price of $493.35 and a mixed return profile. The stock is down 7.8% over the past month and 12.2% year to date, with a 17.9% decline over the past year. Over a three-year period it has delivered 111.2%, and over five years it has delivered 98.7%.

Against that backdrop, the latest focus on AI, system adoption and profitability provides additional context for assessing NasdaqGS:ISRG. The key questions now are how these developments may influence future procedure volumes, recurring revenue potential and the durability of the company’s position in robotic-assisted surgery.

Stay updated on the most important news stories for Intuitive Surgical by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Intuitive Surgical.

Quick Assessment

• ✅ Price vs Analyst Target: The current price of $493.35 sits about 24% below the consensus analyst target of $611.82.
• ❌ Simply Wall St Valuation: Shares are trading at roughly 30.4% above the Simply Wall St estimated fair value, flagged as overvalued.
• ❌ Recent Momentum: The stock has a 30 day return of about 7.8% decline, which may signal short term weakness despite strong business metrics.

There is only one way to know the right time to buy, sell or hold Intuitive Surgical. Head to the Simply Wall St company report for the latest analysis of Intuitive Surgical's Fair Value.

Key Considerations

• 📊 Strong revenue, profitability and global adoption of da Vinci and Ion, plus AI integration, reinforce Intuitive Surgical's position in robotic assisted surgery for investors focused on long term compounding stories.
• 📊 Keep an eye on procedure volumes, recurring instrument and service revenue, and whether earnings growth stays aligned with the current P/E of about 61x and forward P/E of about 56x.
• ⚠️ The shares are flagged as trading 30.4% above estimated fair value, so valuation risk is front and center if sentiment or analyst expectations change.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Intuitive Surgical analysis. Alternatively, you can check out the community page for Intuitive Surgical to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.